| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era
|
Major, Ajay
|
|
|
12 |
6 |
p. e451-e462
|
artikel
|
| 2 |
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series
|
Thanarajasingam, Gita
|
|
|
12 |
6 |
p. e403-e406
|
artikel
|
| 3 |
Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies
|
Bröckelmann, Paul J
|
|
|
12 |
6 |
p. e470-e481
|
artikel
|
| 4 |
Beyond maximum grade: using patient-generated data to inform tolerability of treatments for haematological malignancies
|
Bhatnagar, Vishal
|
|
|
12 |
6 |
p. e463-e469
|
artikel
|
| 5 |
Challenges in managing and reporting adverse events in haematological malignancies in low-income and middle-income countries
|
Nayak, Lingaraj
|
|
|
12 |
6 |
p. e406-e410
|
artikel
|
| 6 |
Concurrent limited cutaneous systemic sclerosis and hereditary haemorrhagic telangiectasia
|
Mathavan, Akash
|
|
|
12 |
6 |
p. e482
|
artikel
|
| 7 |
From prediction to personalisation: optimising blood donation with machine learning
|
Fan, Bingwen Eugene
|
|
|
12 |
6 |
p. e402-e403
|
artikel
|
| 8 |
Internist to fellowship: a path to success
|
Oliver, David
|
|
|
12 |
6 |
p. e413
|
artikel
|
| 9 |
Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial
|
Wang, Xin-Yue
|
|
|
12 |
6 |
p. e442-e450
|
artikel
|
| 10 |
Machine-learning models to predict iron recovery after blood donation: a model development and external validation study
|
Li, Wanjin
|
|
|
12 |
6 |
p. e431-e441
|
artikel
|
| 11 |
Optimising communication to patients with venous thromboembolism: development of a provider toolkit
|
Klok, Frederikus A
|
|
|
12 |
6 |
p. e411-e412
|
artikel
|
| 12 |
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
|
Risitano, Antonio M
|
|
|
12 |
6 |
p. e414-e430
|
artikel
|
| 13 |
Patients first: improving toxicity assessment and reporting
|
The Lancet Haematology,
|
|
|
12 |
6 |
p. e401
|
artikel
|
Tijdschrift beschrijving